Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
EASL International Liver Congress